Log In
BCIQ
Print this Print this
 

ADC3680

  Manage Alerts
Collapse Summary General Information
Company Pulmagen Therapeutics Ltd.
DescriptionOral, small molecule prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2) (CRTH2) (DP2) antagonist
Molecular Target Prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2) (CRTH2) (GPR44) (DP2) (CD294)
Mechanism of ActionProstaglandin D2 (PGD2) receptor subtype DP2 (CRTH2) antagonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/01/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today